Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants

Abstract

Article Tools MOLECULAR TUMOR BOARD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00593 JCO Precision Oncology no. 7 (2023) e2200593. Published online April 7, 2023. PMID: 37027811 Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants Hiba G. Narvel , MBBS1xHiba G. NarvelSearch for articles by this author; So Yeon Kim, MD2xSo Yeon KimSearch for articles by this author; Aspan M. Shokrekhuda, MD3xAspan M. ShokrekhudaSearch for articles by this author; Perry R. Cohen , MD4xPerry R. CohenSearch for articles by this author; K. H. Ramesh, PhD4xK. H. RameshSearch for articles by this author; Sheila R. Solomon , MS5xSheila R. SolomonSearch for articles by this author; Paul K. Paik , MD6xPaul K. PaikSearch for articles by this author; and Balazs Halmos , MD7xBalazs HalmosSearch for articles by this author Show More 1Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY2Department of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT3Department of Radiology, Division of Nuclear Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY4Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY5Guardant Health, Redwood City, CA6Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY7Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY https://doi.org/10.1200/PO.22.00593 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Hiba G. Narvel, So Yeon Kim, Sheila R. Solomon, Balazs HalmosCollection and assembly of data: Hiba G. Narvel, Aspan M. Shokrekhuda, Sheila R. Solomon, Paul K. Paik, Balazs HalmosData analysis and interpretation: Aspan M. Shokrekhuda, Perry R. Cohen, K. H. Ramesh, Sheila R. Solomon, Paul K. Paik, Balazs HalmosManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).So Yeon KimConsulting or Advisory Role: AmgenSheila R. SolomonEmployment: Guardant HealthStock and Other Ownership Interests: Guardant HealthPaul K. PaikHonoraria: Takeda, EMD Serono, Xencor, Bicara Therapeutics, Mirati TherapeuticsConsulting or Advisory Role: EMD Serono, Takeda, Calithera Biosciences, Xencor, Bicara Therapeutics, Mirati TherapeuticsResearch Funding: EMD Serono, Boehringer Ingelheim, Bicara TherapeuticsBalazs HalmosConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Pfizer, Takeda, Novartis, Merck, Bristol Myers Squibb, Turning Point Therapeutics, Apollomics, Janssen Oncology, Veracyte, BeiGene, Arcus BiosciencesResearch Funding: Merck (Inst), AstraZeneca (Inst), Mirati Therapeutics (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Pfizer (Inst), Takeda (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Blueprint Medicines (Inst), Novartis (Inst), Advaxis (Inst), Janssen Oncology (Inst), Elevation Oncology (Inst), Amgen (Inst), BeiGene (Inst), Daiichi Sankyo/Astra Zeneca (Inst)No other potential conflicts of interest were reported.